E75.0 GM2 gangliosidosis

Name of the Condition

• GM2 Gangliosidosis (ICD-10 Code: E75.0)

Summary

GM2 gangliosidosis is a rare inherited lysosomal storage disorder characterized by the accumulation of GM2 ganglioside in neurons and other cells. This buildup disrupts normal cellular function, particularly affecting the nervous system. The condition is part of a broader group of sphingolipid metabolism disorders and presents with progressive neurological decline.

Causes

GM2 gangliosidosis results from genetic mutations that impair the activity of enzymes involved in GM2 ganglioside breakdown. The most common forms are caused by defects in the HEXA or HEXB genes, which encode enzymes necessary for lipid metabolism. Inheritance is typically autosomal recessive, meaning both copies of the gene must be mutated for the condition to manifest.

Risk Factors

• Family history of GM2 gangliosidosis or related lysosomal storage disorders.
• Consanguineous relationships, increasing the likelihood of recessive gene mutations.
• Ethnic backgrounds with higher carrier frequencies (e.g., certain populations with increased prevalence of Tay-Sachs disease).

Symptoms

• Progressive neurological deterioration, including developmental delay or regression.
• Muscle weakness, hypotonia, or spasticity.
• Seizures or abnormal eye movements.
• Loss of motor skills or speech.
• In some cases, cherry-red spots on the retina.

Diagnosis

Diagnosis involves clinical evaluation of neurological symptoms, followed by biochemical testing to measure enzyme activity (e.g., hexosaminidase A or B levels). Genetic testing may confirm mutations in the HEXA or HEXB genes. Prenatal testing is available for at-risk families.

Treatment Options

Treatment is primarily supportive, focusing on managing symptoms and complications. This may include anticonvulsant medications for seizures, physical therapy for motor function, and nutritional support. Enzyme replacement therapy or substrate reduction therapy is under investigation but not widely available.

Prognosis and Follow-Up

Prognosis varies by subtype but is generally poor, with most forms leading to severe neurological impairment and reduced life expectancy. Regular follow-up with neurologists and multidisciplinary care teams is essential to address evolving symptoms and complications.

Complications

• Progressive loss of motor and cognitive function.
• Respiratory complications due to muscle weakness.
• Feeding difficulties or aspiration risk.
• Severe developmental regression.

Lifestyle & Prevention

• Genetic counseling for families with a history of the condition.
• Carrier screening for at-risk populations.
• Prenatal testing options for known carriers.

When to Seek Professional Help

Seek immediate medical attention if symptoms of developmental regression, seizures, or significant motor decline appear, especially in infants or young children. Early diagnosis can help guide supportive care and family planning.

Tips for Medical Coders

Document the specific subtype of GM2 gangliosidosis (e.g., Tay-Sachs disease, Sandhoff disease) when available, as this may impact coding specificity. Ensure clinical documentation supports the diagnosis, including enzyme activity results or genetic testing, to justify the E75.0 code assignment.